Our focus is expanding affordable access to NARCAN® (naloxone HCl) Nasal Spray - the leading
community use naloxone - and progressing our pipeline of opioid overdose and addiction treatments.


ADAPT Pharma® Expands Program Offering Free NARCAN® (naloxone HCl) Nasal Spray to Eligible Schools and Universities  

March 19, 2018

ADAPT Supports President Donald J. Trump and Administration’s Public Health Initiatives to Combat the Opioid Epidemic

March 19, 2018 – ADAPT Pharma® (ADAPT) (www.adaptpharma.com) today announced the expansion of its program offering free NARCAN® (naloxone HCl) Nasal Spray – the leading community use naloxone1 – to U.S. high schools and eligible colleges and universities, including:

  • Expanding free NARCAN® Nasal Spray availability by eliminating the prior 20,000 cartons cap for eligible colleges and universities*
  • Doubling the allocation to high schools from one free carton (two 4mg doses) to two free cartons (four 4mg doses)
  • Extending the term of the free NARCAN® Nasal Spray offer until it is in every high school and eligible college and university in the U.S.

ADAPT Pharma continues to offer first responders such as Law Enforcement and Firefighters a 40% discount off wholesale pricing so these groups and nonprofit community-based organizations can purchase a box of two doses for $75.

“We are committed to expanding affordable access to NARCAN® Nasal Spray to get this emergency treatment for opioid overdose into all places where opioids may be present and into the hands of all who may witness an opioid overdose,” said Seamus Mulligan, Chairman and CEO of ADAPT. “We believe, expanding our program to provide free NARCAN® Nasal Spray to all U.S. high schools and eligible colleges and universities will improve awareness of opioid risks and help in the timely response in the event of an opioid overdose.”

NARCAN® Nasal Spray

NARCAN® Nasal Spray 4mg is the only FDA-approved, needle-free formulation of naloxone for the emergency treatment of a known or suspected opioid overdose. It does not require assembly or any specialized medical training and is also the highest concentrated dose of intranasal naloxone currently available. NARCAN® Nasal Spray is not a substitute for emergency medical care, and additional doses of NARCAN® Nasal Spray may be required until emergency medical assistance arrives. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance. Please see Indications and Important Safety Information below.

Affordable Access and Availability

NARCAN® Nasal Spray is extensively covered by health insurance providers at affordable co-pays. Ninety-four percent of insured lives have access2 and seventy-five percent of co-pays on prescriptions dispensed at retail pharmacies are $10 or less.3 NARCAN® Nasal Spray is available without a physician’s prescription from retail pharmacies in 49 states.

ADAPT offers a 40 percent discounted Public Interest Price of $37.50 per dose ($75 per carton of two doses) for qualifying government or nonprofit organizations, including law enforcement, firefighters, harm reduction groups, schools and community centers.

Donations and Schools Program*

ADAPT has donated more than 40,000 doses of NARCAN® Nasal Spray to community groups, law enforcement, high schools, colleges and universities. This included 5,500 free doses distributed to high schools in 31 states.  In addition, more than 216 colleges and universities in 35 states have participated in the Schools Program since its launch in March 2016.

ADAPT encourages all high schools and Title IV-eligible, degree-granting colleges and universities in the United States to apply for NARCAN® Nasal Spray at www.narcan.com/partnerships. The program will now provide two free cartons to every high school and four free cartons to every Title IV-eligible, degree-granting college and university in the U.S.


NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

Important Safety Information

NARCAN® (naloxone HCI) Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

Adverse Reactions:  The following adverse reactions were observed in a NARCAN® Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.

To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information at: https://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf.

For additional information on NARCAN® Nasal Spray, please visit www.NARCAN.com.

For questions regarding NARCAN® Nasal Spray distribution, please call 1-844-4NARCAN (462-7226).


ADAPT Pharma® is a privately-held company committed to expanding affordable access to NARCAN® (naloxone HCI) Nasal Spray and to progressing treatment options in the field of addiction. ADAPT Pharma’s company headquarters is in Dublin, Ireland with U.S. headquarters in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.

Thom Duddy
Executive Director – Communications 
ADAPT Pharma®

1 Symphony TRx Naloxone Market Analytics, week ending February 23, 2018
2 MMIT Formulary Analytics, September 2017
3 IMS Health, NPA Extended Insights Audit, Jan- Jul 2017